Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation. Results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial

Journal of the American College of Cardiology

Volumn 53, Issue 17, 2009, Pages 1488-1497

  Weisz, Giora ^a   Leon, Martin B ^a   Holmes Jr , David R ^b   Kereiakes, Dean J ^c   Popma, Jeffrey J ^d   Teirstein, Paul S ^e   Cohen, Sidney A ^f,g   Wang, Hong ^g   Cutlip, Donald E ^h   Moses, Jeffrey W ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ST MARY S HOSPITAL   (United States)

^c Ohio Heart and Vascular Center   (United States)

^d ST ELIZABETH'S MEDICAL CENTER   (United States)

^e SCRIPPS CLINIC   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g JOHNSON AND JOHNSON   (United States)

^h HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

coronary disease; diabetes mellitus; restenosis; stents; thrombosis

Indexed keywords

RAPAMYCIN;

ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; STENT THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; CORONARY RESTENOSIS; DOUBLE-BLIND METHOD; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTORS; SIROLIMUS; SURVIVORS; TIME FACTORS;

EID: 64649084378     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.01.050     Document Type: Article

References (28)

1. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
2. Fajadet J., Morice M.C., Bode C., et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 111 (2005) 1040-1044
3. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
4. Holmes Jr. D.R., Leon M.B., Moses J.W., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
5. Weisz G., Leon M.B., Holmes Jr. D.R., et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 47 (2006) 1350-1355
6. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
7. Ong A.T., McFadden E.P., Regar E., de Jaegere P.P., van Domburg R.T., and Serruys P.W. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
8. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
9. Camenzind E., Steg P.G., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115 (2007) 1440-1455 discussion 1455
10. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
11. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
12. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
13. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
14. Waksman R., Ajani A.E., White R.L., et al. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation 109 (2004) 340-344
15. Leon M.B., Teirstein P.S., Moses J.W., et al. Declining long-term efficacy of vascular brachytherapy for in-stent restenosis: 5-year follow-up from the gamma-1 randomized trial. Circulation 110 (2004) III405
16. Gruberg L., Caiati R., Aronson D., et al. Five-year clinical follow up after intracoronary radiation for the prevention of in-stent restenosis. J Invasive Cardiol 18 (2006) 494-498
17. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96 (1997) 1761-1769
18. Hoffman S.N., TenBrook J.A., Wolf M.P., Pauker S.G., Salem D.N., and Wong J.B. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 41 (2003) 1293-1304
19. Cutlip D.E., Chhabra A.G., Baim D.S., et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 110 (2004) 1226-1230
20. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
21. Daemen J., Garcia-Garcia H.M., Kukreja N., et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 28 (2007) 26-32
22. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
23. Kornowski R., Mintz G.S., Kent K.M., et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 95 (1997) 1366-1369
24. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 35 (2000) 1122-1129
25. King III S.B., Kosinski A.S., Guyton R.A., Lembo N.J., and Weintraub W.S. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 35 (2000) 1116-1121
26. Abizaid A., Costa M.A., Centemero M., et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 104 (2001) 533-538
27. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
28. Weisz G., and Stone G.W. Safety and efficacy of drug-eluting stents: on-label and off-label perspectives. Rev Cardiovasc Med 9 (2008) 46-61